Eli Lilly Reports Success With COVID-19 Neutralizing Antibody Treatment

Eli Lilly Reports Success With COVID-19 Neutralizing Antibody Treatment

Get ready for the best coronavirus news we've seen from the biopharmaceutical industry to date. An interim peek at a clinical trial with an experimental treatment from Eli Lilly (NYSE: LLY) suggests LY-CoV555 could be an effective treatment option for COVID-19 patients with mild-to-moderate symptoms.